Skip to content
Pharma Observatory a Scientist.com platform

Organization (Industry)

BRIDGEBIO PHARMA, INC.

ClinicalTrials.gov lists BRIDGEBIO PHARMA, INC. as lead sponsor of 14 trials, counting the companies grouped under it.

US Industry Manufacturer CIK 0001743881
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Companies grouped under this page Companies grouped under this page 4 Disease areas Disease areas 3 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 SEC-reported annual financials SEC-reported annual financials 10 Financing and grant events Financing and grant events 59 FDA untitled letters FDA untitled letters 1 Climate targets, as filed Climate targets, as filed 1 Workforce and board diversity, as filed Workforce and board diversity, as filed 1 Companies grouped under this page Companies grouped under this page 4 Disease areas Disease areas 3 Trials by start year as sponsor or collaborator Trials by start year as sponsor or collaborator 2 SEC-reported annual financials SEC-reported annual financials 10 Financing and grant events Financing and grant events 59 FDA untitled letters FDA untitled letters 1 Climate targets, as filed Climate targets, as filed 1 Workforce and board diversity, as filed Workforce and board diversity, as filed 1

Rows recorded per section (log scale)

3 more sections with rows · 13 sections measured, none recorded

This page covers BRIDGEBIO PHARMA, INC. and 4 companies grouped under it: 14 lead-sponsored trials (0 its own, 14 in the grouped companies) and 4 legal-entity registrations (4 its own, 0 in the grouped companies).

Get the BRIDGEBIO PHARMA, INC. report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Companies grouped under this page (4)

Shown in this order: most lead trials first.

Companies grouped under this page
Company Lead trials Legal entities
Origin Biosciences 5 0
ML Bio Solutions, Inc. 4 0
Phoenix Tissue Repair, Inc. 3 0
Adrenas Therapeutics Inc 2 0

Disease areas (3)

Shown in this order: most trials first.

Disease areas
Disease area Trials
Amyloid Neuropathies, Familial 1
Amyloidosis 1
Heart Failure 1

Trials by start year as sponsor or collaborator (2)

Shown in this order: most recent first. 2026 is partial: trials registered with a 2026 start date so far, not a full year.

Trials by start year as sponsor or collaborator
Year Trials started
2026 (partial year) 1
2025 1

No forecast is made for this organization: it averages 0.4 trial starts a year over the five years to September, under the 5 a year the method needs.

The series also counts trials where the organization is a collaborator; the lead-sponsor trial count does not.

SEC-reported annual financials (10)

Shown in this order: newest fiscal year first; SEC EDGAR XBRL companyfacts, USD as reported.

SEC-reported annual financials
Fiscal year Revenue (USD) Net income (USD) R&D (USD)
2025 502,076,000 not reported 451,953,000
2024 221,902,000 not reported 506,461,000
2023 9,303,000 not reported 455,711,000
2022 77,648,000 not reported 399,462,000
2021 69,716,000 not reported 451,024,000
2020 8,249,000 not reported 337,047,000
2019 40,560,000 not reported 209,947,000
2018 not reported not reported 140,073,000
2017 not reported not reported 30,556,000
2016 not reported not reported not reported

Financing and grant events (59)

Shown in this order: most recent first.

Financing and grant events
Date Round type Amount (USD) Source
2026-07-02 Private placement not disclosed Sec extracted
2026-07-01 Private placement 933,900,000 Sec extracted
2026-05-07 ATM offering not disclosed Sec extracted
2026-05-06 Other financing not disclosed Sec extracted
2026-01-21 Debt financing 619,300,000 Sec extracted

Showing 5 of 59 events.

Start your 14-day trial Email me the first 50 events as a PDF

FDA untitled letters (1)

FDA untitled letters
Issue date Letter
2025-09-09 188687

Climate targets, as filed (1)

Climate targets, as filed
Reporting year Net-zero target
2025 not disclosed

Workforce and board diversity, as filed (1)

Workforce and board diversity, as filed
Reporting year Workforce % women Board % women
2025 not disclosed not disclosed

Organization relationships (1)

Organization relationships
Related organization Relationship Evidence
Yale University Co sponsors trial with 1

Latest dated events (62)

Shown in this order: newest first.

Latest dated events
Date Event Source
2026-07-31 Trial started Clinical trials (ClinicalTrials.gov) (ClinicalTrials.gov, U.S. National Library of Medicine; AACT database, Clinical Trials Transformation Initiative (CTTI))
2026-07-02 Private placement Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2026-07-01 Private placement Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2026-05-07 At-the-market offering Funding rounds and grants (NIH RePORTER + SEC EDGAR)
2026-05-06 Financing Funding rounds and grants (NIH RePORTER + SEC EDGAR)

Showing 5 of 62 events.

Start your 14-day trial Email me the first 50 events as a PDF

Biomarker capability evidence (2)

Shown in this order: tier desc, then gene symbol.

Biomarker capability evidence
Gene Role Evidence
TTR Trial collaborator Named in trial inclusion criteria
TTR Trial collaborator Mentioned in trial text

Not on this page

Checked, with nothing recorded for this organization: related companies not grouped here, active development programs, approved assets, sponsor delivery record, journals published in, us granted patents, fda warning letters, fda inspection record, fda recalls, fda import refusals, manufacturing and distribution sites, clia clinical laboratory certificates, and biomarkers this organization publishes on.